Johnston John Joseph 4
4 · MAXCYTE, INC. · Filed Dec 10, 2024
Insider Transaction Report
Form 4
MAXCYTE, INC.MXCT
Johnston John Joseph
Director
Transactions
- Sale
Common Stock
2024-12-06$3.70/sh−505$1,869→ 141,950 total - Exercise/Conversion
Common Stock
2024-12-09$2.93/sh+891$2,607→ 142,841 total - Sale
Common Stock
2024-12-09$3.79/sh−2,495$9,459→ 141,950 total - Exercise/Conversion
Common Stock
2024-12-09$1.64/sh+1,121$1,840→ 143,962 total - Exercise/Conversion
Common Stock
2024-12-09$2.93/sh+483$1,416→ 144,445 total - Exercise/Conversion
Common Stock
2024-12-06$2.93/sh+505$1,478→ 142,455 total - Exercise/Conversion
Stock Option (right to buy)
2024-12-06−505→ 891 totalExercise: $2.93Exp: 2027-07-14→ Common Stock (505 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-12-09−1,121→ 0 totalExercise: $1.64Exp: 2030-01-20→ Common Stock (1,121 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-12-09−483→ 23,417 totalExercise: $2.93Exp: 2028-07-18→ Common Stock (483 underlying) - Exercise/Conversion
Stock Option (right to buy)
2024-12-09−891→ 0 totalExercise: $2.93Exp: 2027-07-14→ Common Stock (891 underlying)
Footnotes (4)
- [F1]The sales and option exercise reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2023.
- [F2]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.70 to $3.705, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.705 to $3.84, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]This option is fully vested and exercisable.